Department of Chemistry and Chemical Engineering, Shanxi Datong University, Datong, Shanxi, China.
Methods Mol Biol. 2023;2689:95-106. doi: 10.1007/978-1-0716-3323-6_8.
The biophysical signatures of single cells, such as multidrug resistance (MDR), may easily change during their various disease states. Therefore, there is an ever-growing need for advanced methods to study and analyze the response of cancer cells to therapeutic intervention. To determine the cancer cells and responses to various cancer therapies, from a cell mortality perspective, we report a label-free and real-time method to monitor the in situ responses of ovarian cancer cells using a single-cell bioanalyzer (SCB). The SCB instrument was used to detect different ovarian cancer cells, such as NCI/ADR-RES cells, which are multidrug resistant (MDR), and non-MDR OVCAR-8 cells. The discrimination of ovarian cells has been achieved at the single-cell level by measuring drug accumulation quantitatively in real time, in which the accumulation is high in non-MDR single cells without drug efflux but is low in MDR single cells which are not efflux-free. The SCB was constructed as an inverted microscope for optical imaging and fluorescent measurement of a single cell that was retained in a microfluidic chip. The single ovarian cancer cell retained in the chip offered sufficient fluorescent signals for the SCB to measure the accumulation of daunorubicin (DNR) in the single cell in the absence of cyclosporine A (CsA). The same cell allows us to detect the enhanced drug accumulation due to MDR modulation in the presence of CsA, which is the MDR inhibitor. The measurement of drug accumulation in a cell was achieved after it was captured in the chip for one hour, with the correction of background interference. The detection of accumulation enhancement due to MDR modulation by CsA was determined in terms of either the accumulation rate or enhanced concentration of DNR in the single cell (same cell, p < 0.01). It showed that with the effectiveness of efflux blocking by CsA, the intracellular DNR concentration in a single cell increased by threefold against its same cell control. This single-cell bioanalyzer instrument has the ability to discriminate MDR in different ovarian cells due to drug efflux in them by eliminating the interference of background fluorescence and by using the same cell control.
单细胞的生物物理特征,如多药耐药性(MDR),在其各种疾病状态下可能很容易发生变化。因此,人们越来越需要先进的方法来研究和分析癌细胞对治疗干预的反应。为了从细胞死亡率的角度确定癌细胞对各种癌症疗法的反应,我们报告了一种无标记和实时的方法,使用单细胞生物分析仪(SCB)监测卵巢癌细胞的原位反应。SCB 仪器用于检测不同的卵巢癌细胞,如多药耐药(MDR)的 NCI/ADR-RES 细胞和非 MDR 的 OVCAR-8 细胞。通过实时定量测量药物在单细胞中的积累,从单细胞水平上实现了对卵巢细胞的区分,其中非 MDR 单细胞中药物积累较高,而没有药物外排的 MDR 单细胞中药物积累较低。SCB 被构建为倒置显微镜,用于对保留在微流控芯片中的单个细胞进行光学成像和荧光测量。保留在芯片中的单个卵巢癌细胞提供了足够的荧光信号,使 SCB 能够在没有环孢菌素 A(CsA)的情况下测量单个细胞中柔红霉素(DNR)的积累。同样的细胞使我们能够检测到由于 MDR 调节而导致的药物积累增强,CsA 是 MDR 抑制剂。在将细胞捕获到芯片中一个小时后,通过背景干扰的校正,完成了细胞内药物积累的测量。通过 CsA 对 MDR 调节的药物积累增强的检测是通过单个细胞中 DNR 的积累速率或增强浓度来确定的(同一细胞,p<0.01)。结果表明,通过 CsA 有效阻断外排,单个细胞中 DNR 浓度增加了三倍,与同一细胞对照相比。这种单细胞生物分析仪仪器具有通过消除背景荧光干扰并使用同一细胞对照来区分由于其中药物外排而导致的不同卵巢细胞中的 MDR 的能力。